RAFAEL HOLDINGS, INC. Payments to Acquire Debt Securities, Available-for-sale
RAFAEL HOLDINGS, INC. (RFL) reported Payments to Acquire Debt Securities, Available-for-sale of $105.06 million for the 6-month period ending 2024-01-31, per its 10-Q filed 2024-03-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2024-03-14
- RAFAEL HOLDINGS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-01-31 was $57.54M, a 2.71% increase year-over-year.
- RAFAEL HOLDINGS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-10-31 was $47.52M, a 16.80% decline year-over-year.
- RAFAEL HOLDINGS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-07-31 was $38.46M, a 18.88% increase year-over-year.
- RAFAEL HOLDINGS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-04-30 was $53.20M.
- RAFAEL HOLDINGS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $204.80M, a 213.60% increase from fiscal 2022.
- RAFAEL HOLDINGS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $65.31M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2024-01-31 | $57.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-14 | $105.06M 10-Q · filed 2024-03-14 | $143.52M derived: sum of 3 quarters · filed 2024-03-14 | $196.72M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-10-31 | $47.52M 10-Q · filed 2023-12-14 | $85.98M derived: sum of 2 quarters · filed 2023-12-14 | $139.19M derived: sum of 3 quarters · filed 2023-12-14 | $195.20M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-07-31 | $38.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30 | $91.66M derived: sum of 2 quarters · filed 2023-10-30 | $147.68M derived: sum of 3 quarters · filed 2024-03-14 | $204.80M 10-K · filed 2023-10-30 |
| 2023-04-30 | $53.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | $109.22M derived: sum of 2 quarters · filed 2024-03-14 | $166.34M 10-Q · filed 2023-06-13 | $198.69M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-01-31 | $56.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-14 | $113.14M 10-Q · filed 2024-03-14 | $145.49M derived: sum of 3 quarters · filed 2024-03-14 | |
| 2022-10-31 | $57.12M 10-Q · filed 2023-12-14 | $89.47M derived: sum of 2 quarters · filed 2023-12-14 | ||
| 2022-07-31 | $32.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30 | $65.31M 10-K · filed 2023-10-30 | ||
| 2022-04-30 | $32.96M 10-Q · filed 2023-06-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |